Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.53 |
| ▸ | CA1 | P00915 | 8/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2290498 | 1.00 | CA2 (0.53) | CA2CA1PTPN1CA7CA13 | |
| Fluoride SCHEMBL22801398 | 0.97 | CA2 (0.50) | CA2CA1PTPN1CA7CA13 | |
| SCHEMBL37874 | 0.96 | CA2 (0.56) | CA2CA1PTPN1CA7CA13 | |
| SCHEMBL4457449 | 0.96 | CA2 (0.56) | CA2CA1PTPN1CA7CA13 | |
| SCHEMBL23886640 | 0.93 | CA2 (0.53) | CA2CA1PTPN1CA7CA13 | |
| SCHEMBL6275307 | 0.93 | CA2 (0.53) | CA2CA1PTPN1CA7CA13 | |
| SCHEMBL9982903 | 0.93 | CA2 (0.53) | CA2CA1PTPN1CA7CA13 | |
| SCHEMBL6897439 | 0.93 | CA2 (0.53) | CA2CA1PTPN1CA7CA13 | |
| SCHEMBL6652112 | 0.93 | CA2 (0.53) | CA2CA1PTPN1CA7CA13 | |
| SCHEMBL6897756 | 0.93 | CA2 (0.53) | CA2CA1PTPN1CA7CA13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112615047-A | Gel electrolyte diaphragm, preparation method thereof and lithium ion battery | 曙鹏科技（深圳）有限公司 | 2021-04-06 | — | — | CN | claimed |
| CN-105529496-B | Gel polymer electrolyte membrane and preparation method thereof | 湘潭大学 | 2020-11-03 | — | — | CN | claimed |
| US-20240174821-A1 | POLYIMIDE MICROPARTICLES | XEROX CORPORATION (US) | 2024-05-30 | — | — | US | disclosed |
| CN-114464879-B | Self-repairing block polymeric ionic liquid/polyethylene oxide composite solid electrolyte and preparation method thereof | 南京理工大学 | 2024-04-23 | — | — | CN | disclosed |
| US-11908962-B2 | Optoelectronic device comprising perovskites | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-02-20 | — | — | US | disclosed |
| US-11905381-B2 | Polyimide microparticles | XEROX CORPORATION (US) | 2024-02-20 | — | — | US | disclosed |
| EP-3655571-B1 | FABRICATION OF SOLID-STATE BATTERY CELLS | IMEC VZW (BE) | 2023-10-25 | — | — | EP | disclosed |
| EP-4251623-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023177948-A2 | SOLID STATE BATTERY, CERAMIC ELECTROLYTE STRUCTURE, AND METHODS OF MAKING | GENERAL ELECTRIC COMPANY (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230286968-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| EP-4209357-A1 | WRITING SYSTEM WITH HUMIDITY CONTROLLED COLOR | BIC Violex Single Member S.A. (GR) | 2023-07-12 | — | — | EP | disclosed |
| US-7045250-B2 | Non-aqueous electrolyte battery | SANYO ELECTRIC CO., LTD. (JP) | 2006-05-16 | — | — | US | disclosed |
| US-6780543-B2 | CONNECTING MEMBER BETWEEN POSITIVE AND NEGATIVE ELECTRODES IS COMPOSED OF CLAD MATERIAL COMPRISING ALUMINUM OR ALLOY AND AUSTENITIC/OR FERRITE STAINLESS STEEL TO PREVENT CORROSION BY NONAQUEOUS ELECROLYTE, IMPROVING STORAGE STABILITY | SANYO ELECTRIC CO., LTD. (JP) | 2004-08-24 | — | — | US | disclosed |
| US-20040029007-A1 | Non-aqueous electrolyte battery | SANYO ELECTRIC CO., LTD. (JP) | 2004-02-12 | — | — | US | disclosed |
| US-20020192559-A1 | Connecting member between positive and negative electrodes is composed of clad material comprising aluminum or alloy and austenitic/or ferrite stainless steel to prevent corrosion by nonaqueous elecrolyte, improving storage stability | SANYO ELECTRIC CO., LTD. (JP) | 2002-12-19 | — | — | US | disclosed |
| US-20020090552-A1 | Non-aqueous electrolyte battery | SANYO ELECTRIC CO., LTD. (JP) | 2002-07-11 | — | — | US | disclosed |
| EP-0937055-B1 | PROCESS FOR MANUFACTURING d,1-ALPHA-TOCOPHEROL | HOFFMANN LA ROCHE (CH) | 2002-04-03 | — | — | EP | disclosed |
| EP-0937055-A2 | PROCESS FOR MANUFACTURING d,1-ALPHA-TOCOPHEROL | F. HOFFMANN-LA ROCHE AG (CH) | 1999-08-25 | — | — | EP | disclosed |
| US-5908939-A | CONDENSATION OF TRIMETHYLHYDROQUINONE WITH ISOPHYTOL COMPRISES CARRYING OUT THE CONDENSATION IN THE PRESENCE OF BIS-(TRIFLUOROMETHYLSULPHONYL)AMINE OR A METAL SALT THEREOF | ROCHE VITAMINS INC. (US) | 1999-06-01 | — | — | US | disclosed |
| WO-1998021197-A2 | PROCESS FOR MANUFACTURING d,l-α-TOCOPHEROL | F. HOFFMANN-LA ROCHE AG (CH) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286968-A1 | ARYLOXAZOLO SPIRAL RING DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP4B1, CYP1B1 | CA2 4868/4885CA1 4772/4885PTPN1 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.